Sfoglia per AUTORE
MAURO F
Collezione AO Ordine Mauriziano

  

Items : 10

High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study. in Haematologica / Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116.

2023
AOU Alessandria
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
ASL Cuneo 1
AOU Novara

Fazi P; Vignetti M; Piciocchi A; Cuneo A; Foà R; Guarini A; Nanni M; Neri A; De Propris MS; De Novi LA; Visentin A; Vitale C; Albano F; Molinari MC; Pietrasanta D; Mattiello V; Liberati AM; Giordano A; Gottardi D; Patrizi VB; Galieni P; Musuraca G; Deodato M; Arcari A; Tani M; Levato L; Marchetti M; Massaia M; Rigolin GM; et alii...

Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report. in Hematological oncology / Hematol Oncol. 2021 Oct;39(4):570-574. doi: 10.1002/hon.2899. Epub 2021 Jul 13.

2021
AO Cuneo
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara

Foà R; Chiarenza A; Penna G; Gottardi D; Derenzini E; Levato L; Orsucci L; Gattei V; Gentile M; Sanna A; Gozzetti A; Olivieri J; Murru R; Baratè C; Leone M; Stefoni V; Malerba L; Ibatici A; Tisi MC; Marasca R; Chiurazzi F; Varettoni M; Farina L; Del Poeta G; Re F; De Paoli L; Foglietta M; Giordano A; Marchetti M; et alii...

Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study. in Cancers / Cancers (Basel). 2021 Dec 31;14(1):207. doi: 10.3390/cancers14010207.

2021
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU Alessandria
AOU Novara

Piciocchi A; Cuneo A; Foà R; Fazi P; Neri A; Guarini A; Rigolin GM; Nanni M; De Propris MS; Della Starza I; Raponi S; Del Giudice I; Murru R; Ruocco V; Ibatici A; Varettoni M; Laurenti L; Chiarenza A; Zinzani PL; Gentile M; Molinari A; Gozzetti A; Tani M; Musuraca G; Gottardi D; Re F; Orsucci L; Liberati AM; Ilariucci F; et alii...

Efficacy and safety of front-line treatment with ibrutinib and rituximab in unfit patients with chronic lymphocytic leukemia (CLL). First report of the GIMEMA LLC1114 study in Haematologica

2019
ASL Asti
AO Ordine Mauriziano

Mauro FR; Molica S; Paoloni F; Reda G; Trentin L; Marchetti M; Pietrasanta D; Coscia M; Marasca R; Sportoletti P; Gaidano G; Orsucci L; Stelitano C; Di Renzo N; Liberati M; Gottardi D; Re F; Ilariucci F; Zinzani PL; Mannina D; Gozzetti A; Molinari AL; Gentile M; Chiarenza A; Laurenti L; Varettoni M; Ibatici A; Murru R; Tani M; et alii...

Ibrutinib and rituximab as front-line treatment for unfit patients with chronic lymphocytic leukemia (CLL). preliminary results from the Gimema LLC1114 study in HemaSphere

2019
AO Ordine Mauriziano
ASL Asti

Mauro FR; Molica S; Paoloni F; Reda G; Trentin L; Marchetti M; Pietrasanta D; Coscia M; Marasca R; Sportoletti P; Gaidano G; Orsucci L; Stelitano C; Di Renzo N; Liberati AM; Gottardi D; Re F; Ilariucci F; Zinzani P; Mannina D; Gozzetti A; Molinari AL; Gentile M; Consoli U; Laurenti L; Arcaini L; Ibatici A; Murru R; Tani M; et alii...

Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. in Haematologica / Haematologica. 2017 Sep;102(9):e352-e355. doi: 10.3324/haematol.2016.156901. Epub 2017 Jun 8.

2017
AO Ordine Mauriziano
AOU Città della Salute di Torino
AO Cuneo

Piciocchi A; Boncompagni R; Orlando S; Cuneo A; Galieni P; Marasca R; Vannata B; Pozzato G; Efremov DG; Molica S; Coscia M; Massaia M; D'Arena G; Del Poeta G; Mannina D; Mauro FR; Ciolli S; Autore F; Innocenti I; Laurenti L; Vincelli D; Liberati AM; Russo F; Foá R;

Efficacy and safety of chlorambucil plus rituximab as front-line therapy in elderly and/or unfit patients with chronic lymphocytic leukemia. A gimema retrospective study in Haematologica

2015
AO Ordine Mauriziano

Laurenti L; Autore F; Innocenti I; Vannata B; Ciolli S; Mauro FR; Mannina D; Del Poeta G; D'Arena G; Massaia M; Coscia M; Molica S; Pozzato G; Marasca R; Galieni P; Cuneo A; Orlando S; Piciocchi A; Boncompagni R; Vincelli D; Liberati AM; Russo F; Foà R;

Long term rectal function after high-dose prostatecancer radiotherapy: results from a prospective cohort study. in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology / Radiother Oncol. 2014 Feb;110(2):272-7. doi: 10.1016/j.radonc.2013.09.028. Epub 2013 Dec 11.

2014
ASL Torino 4
AO Ordine Mauriziano

Fellin G; Rancati T; Fiorino C; Vavassori V; Antognoni P; Baccolini M; Bianchi C; Cagna E; Borca VC; Girelli G; Iacopino B; Maliverni G; Mauro FA; Menegotti L; Monti AF; Romani F; Stasi M; Valdagni R;

Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: The case of previous abdominal surgery. Results from a prospective trial in Radiotherapy and Oncology

2012
AO Ordine Mauriziano

Valdagni R; Vavassori V; Rancati T; Fellin G; Baccolini M; Bianchi C; Cagna E; Gabriele P; Mauro F; Menegotti L; Monti AF; Stasi M; Fiorino C;

Modeling fecal incontinence symptoms 6 years after high-dose radiation for prostate cancer: Clinical and dosimetric predictors in Journal of Clinical Oncology

2012
AO Ordine Mauriziano

Fellin G; Rancati T; Fiorino C; Vavassori V; Cagna E; Mauro F; Malinverni G; Valdagni R;